Quadrature Capital
RIGL icon

Quadrature Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Quadrature Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,181
Closed -$329K – 1979
2026
Q1 		$329K Buy
12,181
+359
+3% +$12.1K ﹤0.01% 934
2025
Q4 		$506K Buy
+11,822
New +$446K 0.01% 693

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrature Capital's RIGL Position: Q2 2026 in Review

Quadrature Capital sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 12,181 shares — an estimated $329K sold.

Quadrature Capital first reported a position in RIGL in Q4 2025 and held it in 2 quarters. The position peaked at $506K in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Quadrature Capital reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 12,181 Rigel Pharmaceuticals shares in Q2 2026, an estimated $329K.
  • Quadrature Capital first reported a position in Rigel Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Quadrature Capital's Rigel Pharmaceuticals position peaked at $506K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.